Literature DB >> 15029100

Early referral to a nephrologist is associated with better outcomes in type 2 diabetes patients with end-stage renal disease.

L Frimat1, C Loos-Ayav, V Panescu, N Cordebar, S Briançon, M Kessler.   

Abstract

OBJECTIVE: End-stage renal disease (ESRD) requiring renal replacement therapy (RRT) is a late complication of type 2 diabetes. The correlation between pre-ESRD medical care and outcome has been rarely studied in France.
METHODS: Community-based study of case-incIdent ESRD patients. Medical care practices were described retrospectively when starting RRT. Medical status, mortality, morbIdity, and quality-of-life were recorded prospectively.
RESULTS: One hundred and fourty-eight ESRD patients with type 2 diabetes were included. Factors independently correlated with mortality within 3 Months of RRT onset were presence of physical impairment of ambulation at onset of RRT [odd ratio (OR): 5, (95%CI: 1.9-13.3)], and starting RRT in life-threatening circumstances [OR: 3.6, (95%CI: 1.2-10.7)]. Factors independently correlated with "poor outcome" 1 Year after the onset of RRT were BMI less than 20 kg/m2 [OR: 13.4, (95%CI: 1.5-120.2)] and presence of 2 [OR: 2.7, (95%CI: 0.9-8.4)], or 3 or more comorbId conditions [OR: 4, (95% CI: 1.4-11)]. Three Months after the first RRT session, survival was 16.4% better for patients who had had regular nephrological care versus none, and 9.1% better for those who had had late nephrological care versus none. Type 2 diabetes patients starting RRT in an emergency setting had had significant less regular nephrological care. Length of their first hospital stay was significantly longer. They were more likely to have lower resIdual renal function, gastrointestinal symptoms, lower serum albumin, lower hematocrit, lower serum calcium, and higher serum phosphorus.
CONCLUSIONS: During the course of chronic renal failure in type 2 diabetes patients, early implementation of nephrological well-established guIdelines is associated with better outcome after starting RRT.

Entities:  

Mesh:

Year:  2004        PMID: 15029100     DOI: 10.1016/s1262-3636(07)70091-5

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  7 in total

1.  Prevalence of pre-end-stage renal disease care and associated outcomes among urban, micropolitan, and rural dialysis patients.

Authors:  Saugar Maripuri; T Alp Ikizler; Kerri L Cavanaugh
Journal:  Am J Nephrol       Date:  2013-03-16       Impact factor: 3.754

Review 2.  Chronic kidney disease prediction is an inexact science: The concept of "progressors" and "nonprogressors".

Authors:  Macaulay Amechi Chukwukadibia Onuigbo; Nneoma Agbasi
Journal:  World J Nephrol       Date:  2014-08-06

3.  Late referral of patients with end-stage renal disease: an in-depth review and suggestions for further actions.

Authors:  Gernot Baer; Norbert Lameire; Wim Van Biesen
Journal:  NDT Plus       Date:  2009-04-29

4.  End stage renal disease in French Guiana (data from R.E.I.N registry): South American or French?

Authors:  Dévi Rita Rochemont; Mohamed Meddeb; Raoul Roura; Cécile Couchoud; Mathieu Nacher; Célia Basurko
Journal:  BMC Nephrol       Date:  2017-06-30       Impact factor: 2.388

5.  Risk Factors for Unplanned Dialysis Initiation: A Systematic Review of the Literature.

Authors:  Rana Hassan; Ayub Akbari; Pierre A Brown; Swapnil Hiremath; K Scott Brimble; Amber O Molnar
Journal:  Can J Kidney Health Dis       Date:  2019-03-13

6.  Estimated GFR reporting is not sufficient to allow detection of chronic kidney disease in an Italian regional hospital.

Authors:  Giorgio Gentile; Maurizio Postorino; Raymond D Mooring; Luigi De Angelis; Valeria Maria Manfreda; Fabrizio Ruffini; Manuela Pioppo; Giuseppe Quintaliani
Journal:  BMC Nephrol       Date:  2009-09-01       Impact factor: 2.388

7.  Timing of nephrology referral: influence on mortality and morbidity in chronic kidney disease.

Authors:  Sushanth Kumar; Jayakumar Jeganathan
Journal:  Nephrourol Mon       Date:  2012-06-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.